Introduction
Researchers designing anti-tumor vaccines, or treatments involving transfers of activated antitumor cells, have long focused on methods to elicit tumor-specific CD8 cytotoxic T cells (CTL), envisioning that their potent ability to kill tumor targets in vitro, and to reject transplants in vivo, would translate into equally potent anti-tumor activity in vivo. Although many of the resulting treatments have indeed been able to elicit CTLs that recognize tumor cells and/or tumor antigens in vitro, complete tumor regression has been achieved in only a minority of patients [1] [2] [3] [4] [5] . Animal only.
For personal use at PENN STATE UNIVERSITY on February 22, 2013 . bloodjournal.hematologylibrary.org From models have generated similar results. In a few cases, the transfer of monoclonal TCR Tg CD8 T cells was able to clear small tumors 6 , but in most, the TCR Tg CD8 cells were ineffective without the addition of other aids. In short, though CD8 CTL can clear tumors, they most often don't, unless helped by additional treatments [6] [7] [8] [9] [10] [11] [12] .
Over the last 25 years, there have been a few studies showing that CD4 T cells could also clear tumors, completely independently of CD8s [13] [14] [15] [16] [17] . Nevertheless CD4 T cells continue to be studied mainly for their role as helpers for CD8 CTL 11, 18, 19 , and it has even been suggested that tumor-specific CD4 T regulatory cells could act as suppressors of anti-tumor responses 20 . Thus, their potential as CD8-independent anti-tumor effectors has gained only a few proponents [13] [14] [15] [16] [17] [21] [22] [23] [24] , and only a few of the newly designed cancer vaccines incorporate antigens to stimulate CD4 cells, mostly in order to enhance their helper activity 25, 26 , while most studies using adoptive transfer of tumor specific T cells continue to focus entirely on CD8 cells 2, 3, [27] [28] [29] [30] .
We decided to do a direct comparison between CD4 and CD8 T cells specific for the same tumor, using TCR Tg mice containing pure populations of CD4 or CD8 T cells, so as to test each type of effector alone, without the effects of potential contaminants. To our surprise, we found that CD4 cells were actually better than CD8 cells at rejecting tumors in every case we tested ( only.
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Materials and methods

Mice
The anti-H-Y TCR transgenic mice MataHari, Marilyn and Rachel, and the H-2 b or H-2 k CD3KOγcKO mice have been described previously 31, 32 . They, and C57BL/6 (B6), C57BL/10-Rag2KO and C57BL/10-Rag2KOγcKO mice were obtained from Taconic Farms (Germantown, NY) and housed in specific pathogen-free conditions. The NIH is an AALAC-accredited facility.
Tumor cells
We used MB49, an H-2 b bladder carcinoma 33 , βTC-tet, an H-2 k pancreatic β-cell tumor 34 , TRAMP-C2, an H-2 b prostate adenocarcinoma 35 , WR21, an H-2 b salivary gland adenocarcinoma 36 . IP2-E4, 3B-11 and 2F-2B are H-2 k tumor cell lines obtained from a single C3H/HeJ endothelioma 37 . 2F-2B and B16, an H-2 b melanoma, are negative for H-Y. WR21, TRAMP-C2, IP2-E4, 3B-11 and 2F-2B were from ATCC (Manassas, VA). The lines were cultured in complete IMDM (IMDM medium plus 10% FCS, glutamine and antibiotics) and tested to be pathogen-free (IMPACT test) before the in vivo experiments. Tumor cells were occasionally cultured for 2 days with 500 IU/mL of recombinant mouse IFN-γ (R&D System, Minneapolis, MN) to induce MHC Class II expression.
Tumor challenge
Unless otherwise noted, 10 5 cells in 100 µl of PBS were injected subcutaneously into the right flank. Tumor size was measured every 3-4 days and the volume calculated as length x width x height/2. Mice were sacrificed if they became distressed or if tumor volume became >1,000 mm 3 .
For the βTC-tet pancreatic tumor, after seven days of tumor challenge, blood glucose levels were measured every day and tumors were considered established when glucose levels were < 3 mM.
only.
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RT-PCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA), and reverse transcribed. PCR was performed using the following primers: Dby-Forward: 5'-CAATAGCAGCCGAAGTAGTGGTAGT-3', reverse: 5'-AACTGCCTGGGAGTTATAATTTCCT-3'; Uty-Forward: 5'-GCTCACTTATATGAAACCCAGAGGAA-3', reverse: 5'-CATATTATGGTGCATCCAACCTAACT-3'. To check for genomic DNA contamination, we prepared parallel samples without reverse transcriptase (RT-control).
Flow cytometry
After blocking non-specific binding with ultra-block solution (a mixture of rat, hamster and mouse sera with 10 µg/ml 2.4G2 mAb), cells were stained with various combinations of the following monoclonal antibodies: PE-labeled anti-H-2D b or anti-H-2A b or anti-NK1.1, FITClabeled anti-CD4 or anti-CD8, biotin-conjugated anti-CD45.2 or anti-TCRVβ6 or anti-TCRVβ8, which were followed by streptavidin-APC incubation, (all from BD Pharmingen), and APClabeled D b -Uty tetramer (NIAID tetramer facility). Dead cells were excluded by staining with 7AAD (BD Pharmingen).
Adoptive transfer and in vitro killing assay
One day after tumor challenge mice received 10 6 cells (unless otherwise mentioned) from freshly isolated spleen and mesenteric lymph nodes (MLN) of the TCR transgenic mice, or the same cells previously primed in vitro. In vitro stimulation with or without 10% Concanavalin A supernatant (CAS) (BD Biosciences, Bedford, MA) was performed as described 38 . In some experiments, the only.
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Proliferation assay
Marilyn spleen cells (10 5 per 0.2 ml/well) were cultured for three days in complete IMDM plus 2-mercaptoethanol with various numbers of mitomycin C (Sigma, St. Louis, MO) treated spleen or tumor stimulators as a source of antigen. The stimulators were titrated (three fold dilutions): the highest numbers per well were: male and female spleen cells = 5x10 5 , MB49 and B16 = 1.5x10 4 .
3 H-thymidine was added for the last 18 hours of culture. Cells were harvested and incorporated thymidine quantified. 
CFSE labelling and in vivo killing assay
Depletion of NK cells
In vitro depletion of NK cells from Marilyn spleen and LN was done with Miltenyi beads (Auburn, CA) coated with rat anti-mouse DX5 antibodies following the manufacturer's instructions. In vivo depletion of NK cells was achieved by intraperitoneal injections of 100 µg of the mouse IgG2a anti-NK1.1 antibody, PK136, with the mouse IgG2a anti-E k antibody 14-4-4S as control. Both were purified from hybridoma supernatants by the NIAID antibody facility.
Antibodies were given three days before tumor challenge, again at day one (together with Marilyn cells transfer) and every 7 days until no tumor-bearing mice remained. Successful depletion was tested by FACS analysis of spleen, lymph nodes and tumors, using DX5 and NK1.1 antibodies (data not shown).
Results
The model system 31, 41 . For the first model tumor, we chose the B6-male bladder carcinoma MB49, which expresses both Uty ( 33 and Figure 1B 
Analysis of the CD8 T cells' lack of in vivo anti-tumor effect
The poor anti-tumor effect of MataHari splenocytes was somewhat surprising, as they are extremely potent CTLs ( Figure 1D ), make IFNγ in vitro 31 , and rapidly reject male skin grafts in vivo, both by direct and indirect means 31 . One possibility arose from recent studies in which CD8 T cells were refractive to secondary stimulation if they had been primed in the absence of help 42 . To test whether the lack of tumor rejection was due to an absence of help during the activation phase 43 Figure 3G ).
A similar disconnect between surrogate tests of effector function vs. actual tumor clearance has been seen in other studies in humans 1,5 and mice 7, 10, 47 , where CD8 T cells that were effective in in vitro tests were nevertheless poor at clearing growing tumors in vivo. This is thus a widely known phenomenon that has lead to the suggestion that some tumors may outpace the CD8 killers 6, 47, 48 , or that the tumor environment impairs T cell effector function 49 .
How then were the CD4 Marilyn cells able to reject MB49?
Marilyn does not need to directly bind the tumor
Figures 1D and 3C show that Marilyn cells exhibited a small amount of killing activity against male targets, suggesting that Marilyn might recognize Dby/A b complexes on the tumor surface.
In vivo, such recognition could lead to several outcomes. On the one hand, class II/H-Y complexes on tumor cells could act as direct targets for killing by CD4 effectors. On the other hand, class II expression by tumor cells might induce tolerance in tumor-specific CD4 T cells 50, 51 . To test these possibilities, we used two approaches. First, we created a stable transfectant of MB49, using shRNA for the α chain of A b , to reduce the amount of MHC complexes on the only.
For and thus cannot be recognized directly by MataHari or Marilyn T cells 41 . Figure 4C shows that the CD4 Marilyn cells, but not the MataHari cells, were able to clear the H-2 k male tumor, though they could not directly recognize it, demonstrating that MHC class II expression on the tumor was not necessary for tumor clearance.
Host cross presentation at the priming and effector phases For Figure 5A and B show that both cells responded well, with MataHari reaching 79% fully divided cells (a 9 fold increase over the 9% space-induced expansion in tumor free hosts), and Marilyn cells increasing 8 fold from 4% to 33%. Thus it seems that the efficiency of stimulatory antigen crosspresentation by host APCs was quite effective for both antigens, allowing for good priming of both cell types. Marilyn's superiority to MataHari is therefore not due to a lack of cross priming of the CD8 CTL.
To test whether there might also be a role for host-cell-mediated cross-presentation to shows that NK depleted recipients behaved exactly like γc-deficient recipients. In the absence of NK cells, the transferred Marilyn cells were able to delay tumor growth, but it grew out at later time points. These data suggest that the early phase of the CD4 T cell anti-tumor response may be NK-cell independent, whereas long term tumor clearance requires host NK cells. To see if the NK cells migrated to the tumor site, or if they might be acting only in the draining node (perhaps by supplying IFNγ to maintain a Th1 response 53 ), we stained the tumor for the presence of Marilyn CD4 cells and for NK cells. Figure 6C shows that both types of cells were present in the tumor mass, suggesting that they may be working in concert at the tumor site.
Generalizing the results to other CD4 T cells and other tumors
To see if Marilyn's anti-tumor effect could be generalized to other CD4 cells, we tested Rachel, a different TCR-Tg mouse that has slightly higher avidity for Dby/A b 32 . Although not as effective as Marilyn, Rachel cells were nevertheless more effective than MataHari ( Figure 2B and 3B), delaying tumor growth for several weeks ( Figure 7A ). 2) Both Marilyn T cells (Fig 7C) and Rachel T cells ( Figure S9 ) were more effective than
MataHari against H-2 k tumors they could not directly bind to. MataHari, in fact had no effect at all on these tumors. 3) Marilyn cells did not reject the H-Y negative 2F-2B, showing that the CD4 cells do not act nonspecifically, but that their effect is tumor-antigen dependent, though the antigen-specific contact need not be on the tumor itself, and may be mediated partially via nonantigen specific NK cells.
Discussion
Because of their capacity to kill in vitro, the universality of MHC class I expression, and the availability of reagents to identify them, CD8 cells have been the main focus of several decades of research in anti-tumor immunotherapy. Our data suggest that, at least in some cases, CD4 T cells might actually do a better job than CD8s. The data showed that:
1) Tumor specific CD4-T cells were able to eliminate a wide variety of tumors that were resistant to CD8-mediated rejection.
2) CD4 cells partnered with NK cells for complete tumor clearance.
3) Lack of MHC expression by the tumor did not lessen the anti-tumor effect of the CD4 effector cells 4) Neither the anti-tumoral effect of the CD4-T cells, nor the ineffectiveness of the CD8-T cells was predictable from their in vitro or in vivo killing activity.
For personal use at PENN STATE UNIVERSITY on February 22, 2013. bloodjournal.hematologylibrary.org From Let us take these areas in turn. First, although the last 25 years have seen occasional reports in which CD4 cells cleared tumors without the aid of CD8 cells [13] [14] [15] [16] [17] , the relative efficacy of the two types of effectors has never before been evaluated, and the prevailing view is that the immune system's preeminent anti-tumor weapons are the CD8 T cells. The majority of antitumor therapies therefore continue to focus on CD8 killers, occasionally including CD4 cells as potential helpers. However, most CD8-oriented treatments give poor results in human trials In some cases, the CD8 cells were specific for unique stromal antigens 62, 63 , whereas in others they targeted tumor antigens cross-presented by the stromal cells 16, 64 . CD4 T cells might be expected to more efficiently recognize stromal cells cross-presenting tumor antigens, as cross only.
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